INJECTABLE
  • Animeal
  • Animeal

INJECTABLE

TRINEUROSOL HP INJ

TRINEUROSOL HP INJ

By WOCKHARDT

₹ 65.73
₹ 65.73
Unlock Unbeatable offers! WhatsApp us now
Tax included. Shipping calculated at checkout.

Out of Stock

Pack - 5mL
Expires on or after: Feb, 2027
Title

Check Availability

Rapid 3-4 Day Delivery,Tiny Extra Fee!

  • AnimealPet Safe
  • AnimealBest Quality
  • AnimealFast Delivery
  • AnimealSecure Payment
View full details

Trineurosol-HP Injection is a standout product in our VETERINARY VITAMIN INJECTABLE category. Crafted with utmost pharmaceutical precision by Tridoss Laboratories Pvt. Ltd. a trusted Indian pharmaceutical manufacturer this injectable delivers Hydroxocobalamin, the most biologically superior and clinically preferred form of parenteral Vitamin B12, directly into the systemic circulation via intramuscular or subcutaneous injection bypassing the gastrointestinal absorption pathway that is frequently impaired in the very animals that need B12 supplementation most. Unlike Cyanocobalamin the cheaper and more commonly used synthetic B12 form Hydroxocobalamin is the naturally occurring, biologically active cobalamin that binds directly to plasma proteins for superior tissue retention, has a significantly longer plasma half-life that reduces injection frequency requirements, and does not require hepatic conversion before becoming biologically active. For animals with pancreatic exocrine insufficiency, chronic intestinal malabsorption, inflammatory bowel disease, or severe dietary B12 deficiency conditions where oral B12 supplementation is completely ineffective parenteral Hydroxocobalamin injection is the only reliable therapeutic option for achieving and maintaining adequate tissue B12 levels. With Trineurosol-HP, you can trust that you are offering every animal patient the very best in pharmaceutical-grade, biologically superior parenteral B12 repletion.

Composition:

Each 1ml ampoule of Trineurosol-HP Injection contains a precisely formulated, pharmaceutical-grade composition for reliable parenteral delivery:

  • Hydroxocobalamin 1000mcg/ml (Active Ingredient): the naturally occurring, biologically active form of Vitamin B12 distinguished from the synthetic Cyanocobalamin form by its superior pharmacokinetic profile in three clinically important ways. First, Hydroxocobalamin binds avidly to transcobalamin transport proteins in plasma, achieving significantly higher and more sustained tissue B12 concentrations than Cyanocobalamin following injection. Second, its longer plasma half-life means effective therapeutic B12 tissue concentrations are maintained for significantly longer periods between injections reducing treatment frequency requirements and improving practical compliance in clinical practice. Third, unlike Cyanocobalamin which must first be converted to Hydroxocobalamin or Methylcobalamin by hepatic metabolism before becoming biologically active, Hydroxocobalamin enters the active coenzyme pool directly delivering faster, more complete, and more reliable therapeutic action in the two critical B12-dependent enzymatic pathways: the methylcobalamin pathway (methionine synthesis, DNA methylation, and folate metabolism) and the adenosylcobalamin pathway (propionate metabolism and the methylmalonyl-CoA to succinyl-CoA conversion essential for neurological myelin sheath maintenance)
  • Sodium Chloride IP (Isotonic Vehicle): a pharmaceutical-grade isotonic saline base that maintains the osmolality of the injectable solution within the physiological range ensuring minimal tissue irritation, vascular compatibility, and patient comfort upon intramuscular or subcutaneous injection
  • Glacial Acetic Acid / Sodium Acetate (pH Buffer): a pharmaceutical buffer system that maintains the solution pH at the optimal range for Hydroxocobalamin stability and parenteral bioavailability preventing chemical degradation of the active ingredient during storage and ensuring complete solubility and stability at the time of injection
  • Water for Injection IP (Sterile Vehicle): sterile, pyrogen-free water meeting Indian Pharmacopoeia standards for parenteral preparations the aqueous base delivering the active ingredient in a completely clear, injectable solution free from particulate matter and microbial contamination

Definitive Treatment for Vitamin B12 Deficiency Anaemia: the single most important and clinically validated veterinary application of parenteral Hydroxocobalamin providing rapid, complete, and reliable correction of B12 deficiency megaloblastic and macrocytic anaemia in dogs, cats, and large animals where oral B12 supplementation cannot be reliably absorbed. Haematological response including reticulocytosis, rising haemoglobin, and normalisation of red blood cell morphology is typically observed within the first 5 to 10 days of initiating parenteral B12 therapy

Essential Support for Exocrine Pancreatic Insufficiency (EPI): one of the most clinically important veterinary indications for parenteral B12 in dogs EPI causes profound malabsorption of dietary Vitamin B12 through multiple mechanisms including loss of intrinsic factor secretion, bacterial overgrowth consuming dietary B12, and mucosal malabsorption. Virtually all dogs with EPI have significant B12 deficiency that cannot be corrected by oral supplementation alone, making regular parenteral Hydroxocobalamin injection an essential component of comprehensive EPI management alongside enzyme replacement therapy

Chronic Intestinal Malabsorption & Inflammatory Bowel Disease: cats and dogs with chronic enteropathies, protein-losing enteropathy, severe IBD, and intestinal lymphangiectasia frequently develop clinically significant B12 deficiency due to impaired ileal absorption of the B12-intrinsic factor complex parenteral Hydroxocobalamin bypasses this impaired absorptive pathway entirely, delivering therapeutic B12 directly into the systemic circulation regardless of gastrointestinal absorptive status

Neurological Support & Peripheral Neuropathy Management: Vitamin B12 is the essential cofactor for adenosylcobalamin-dependent enzymes responsible for maintaining the structural and functional integrity of the myelin sheath that insulates peripheral nerve axons. B12 deficiency causes progressive demyelination of peripheral nerves resulting in weakness, ataxia, proprioceptive deficits, and sensory neuropathy parenteral Hydroxocobalamin arrests this neurological deterioration and supports myelin repair and remyelination when initiated before irreversible axonal damage occurs

Recovery Support in Debilitated, Post-Surgical & Chronically Ill Animals: the B-complex metabolic roles of Vitamin B12 in energy metabolism, protein synthesis, and DNA replication make it an important supportive supplement for debilitated, post-surgical, anorexic, and chronically ill animals requiring intensive nutritional rehabilitation supporting faster recovery, improved appetite, and restoration of cellular metabolic function

Supports Appetite Stimulation & Weight Gain: clinical experience consistently demonstrates that B12-deficient animals particularly cats with chronic disease and dogs with EPI show significant improvement in appetite, food intake, and body weight following correction of B12 deficiency with parenteral Hydroxocobalamin, as B12 plays a fundamental role in the hypothalamic regulatory pathways that control appetite and satiety

Superior Plasma Retention & Tissue Saturation vs Cyanocobalamin: the significantly superior plasma protein binding and longer half-life of Hydroxocobalamin compared to Cyanocobalamin means that a single therapeutic injection achieves higher peak tissue B12 concentrations that are maintained for longer delivering more complete tissue B12 saturation and a more durable therapeutic response with fewer injections required to maintain adequate B12 status in deficient patients

Cyanide Antidote Action: a unique additional clinical property of Hydroxocobalamin not shared by other B12 forms the cobalt centre of Hydroxocobalamin has an extremely high binding affinity for cyanide ions, forming the stable, non-toxic cyanocobalamin compound that is safely eliminated in urine. This property has been exploited in emergency medicine for cyanide poisoning antidote therapy a use that veterinarians may encounter in cases of smoke inhalation or toxic plant ingestion in companion animals

How to Use:

For intramuscular (IM) or subcutaneous (SC) administration by or under the direct supervision of a licensed veterinarian only. Inspect each ampoule visually before use the solution should be clear, deep red in colour, and free from particulate matter. Do not use if the solution appears cloudy, discoloured, or contains visible particles. Draw the required dose into a sterile syringe using aseptic technique. Administer by deep intramuscular injection into an appropriate injection site or by subcutaneous injection as clinically appropriate. Protect drawn solution from light Hydroxocobalamin is photosensitive and should be administered promptly after drawing into the syringe.

Storage Advice:

Store Trineurosol-HP Injection below 25°C in a cool, dry place. Protect strictly from light Hydroxocobalamin is highly photosensitive and exposure to light causes rapid chemical degradation and loss of potency. Store in the original carton until the point of use. Do not freeze. Keep out of reach of children. Do not use after the expiry date printed on the ampoule label and outer carton. Use immediately after opening do not store opened or partially used ampoules.

About the Brand:

Trineurosol-HP is manufactured by Tridoss Laboratories Pvt. Ltd. a trusted Indian pharmaceutical manufacturer with a strong track record of delivering consistent quality pharmaceutical injectable formulations to healthcare professionals and veterinarians across India. With manufacturing facilities operating under strict GMP quality standards and a commitment to pharmaceutical-grade active ingredient purity and concentration accuracy in every ampoule, Tridoss Laboratories ensures that every dose of Trineurosol-HP delivers the reliable, precisely dosed, biologically superior Hydroxocobalamin that veterinarians and their animal patients depend upon for consistent therapeutic outcomes. Their commitment to accessible, quality-assured pharmaceutical manufacturing aligns perfectly with Animeal's mission to provide registered veterinary professionals across India with reliable procurement access to the full spectrum of veterinary pharmaceutical needs.

Disclaimer:

Trineurosol-HP Injection is a prescription-only injectable medicine that must be prescribed and administered exclusively by or under the direct supervision of a licensed veterinarian. It is not available for self-administration or over-the-counter dispensing. Vitamin B12 deficiency in companion animals is frequently a clinical sign of significant underlying disease including exocrine pancreatic insufficiency, inflammatory bowel disease, intestinal lymphangiectasia, and chronic enteropathy that requires comprehensive veterinary diagnosis and management beyond B12 supplementation alone. Always investigate and address the underlying cause of B12 deficiency in parallel with parenteral B12 repletion therapy. Serum Vitamin B12 measurement before and during therapy is recommended where available to guide therapeutic decision-making and monitor response. Animeal facilitates enquiry and procurement for registered veterinary professionals this product is available for veterinary clinic and hospital procurement only.

Q: Why is Hydroxocobalamin preferred over Cyanocobalamin for veterinary parenteral B12 therapy?
Hydroxocobalamin offers three clinically important pharmacokinetic advantages over the more commonly available and cheaper Cyanocobalamin form. First, it binds avidly to plasma transcobalamin proteins, achieving higher peak tissue B12 concentrations and maintaining them for significantly longer following injection. Second, its longer plasma half-life means effective therapeutic B12 tissue levels are maintained between injections for a more extended period reducing injection frequency requirements and improving practical treatment compliance. Third, unlike Cyanocobalamin which requires hepatic conversion before becoming biologically active, Hydroxocobalamin enters the active coenzyme pool directly delivering faster and more complete therapeutic action in the methylcobalamin and adenosylcobalamin pathways critical for haematological and neurological health respectively.
Q: How quickly will I see clinical improvement after starting parenteral B12 therapy in a B12-deficient dog or cat?
The haematological response to parenteral Hydroxocobalamin therapy in B12-deficient animals is typically rapid and clinically measurable. A reticulocytosis (increase in immature red blood cell precursors in circulation the first sign of haematopoietic recovery) is usually detectable within 5 to 7 days of the first injection. Rising haemoglobin and improving packed cell volume are typically measurable within 2 to 3 weeks. Clinical improvement in appetite, energy level, and body weight in dogs with EPI and cats with chronic disease is often noticed by owners within 2 to 4 weeks of initiating regular parenteral B12 therapy. Neurological improvement in animals with B12 deficiency neuropathy is typically slower requiring 4 to 8 weeks of therapy and is only achievable if treatment is initiated before irreversible axonal damage has occurred.
Q: Why can't B12-deficient animals with EPI or IBD simply take oral B12 supplements instead of injections?
In healthy animals with intact gastrointestinal function, dietary Vitamin B12 absorption occurs through a complex process involving intrinsic factor secretion by the pancreas and stomach, B12-intrinsic factor complex formation, and specific receptor-mediated absorption in the ileum. In dogs with EPI, this process is severely impaired through multiple mechanisms loss of pancreatic intrinsic factor secretion, secondary small intestinal bacterial overgrowth consuming dietary B12 before it can be absorbed, and mucosal malabsorption. In cats and dogs with IBD and chronic enteropathy, ileal mucosal damage impairs receptor-mediated absorption of the B12-intrinsic factor complex. In both conditions, oral B12 supplementation regardless of dose cannot reliably achieve or maintain adequate serum and tissue B12 levels, making parenteral injection the only therapeutically reliable route for B12 repletion in these patients.
Q: Is long-term parenteral B12 supplementation safe for dogs and cats?
Yes Vitamin B12 is a water-soluble vitamin with an extremely wide therapeutic index and no known toxicity at any clinically relevant dose in dogs or cats. Excess Hydroxocobalamin that is not bound to plasma proteins and tissue receptors is safely eliminated in the urine. Long-term monthly or bi-monthly parenteral B12 maintenance therapy is routinely and safely used in dogs with EPI and cats with chronic intestinal disease throughout their entire lives with no adverse effects associated with long-term use. Regular monitoring of serum B12 levels where available helps optimise injection frequency and confirm that maintenance therapy is achieving adequate tissue B12 saturation.
Q: How can veterinary clinics procure Trineurosol-HP Hydroxocobalamin 1000mcg Injection through Animeal?
Registered veterinary practitioners, veterinary clinics, and animal hospitals can enquire about and procure Trineurosol-HP Injection through Animeal's dedicated veterinary pharmaceutical enquiry channel. Please use the Enquire Now button on this product page or contact our veterinary pharma team directly via WhatsApp or phone with your valid veterinary prescription and practice registration details. Our team will respond promptly with product availability, current pricing, pack size options, and delivery arrangements to your registered clinic or hospital address anywhere across India.
TRINEUROSOL HP INJ - Animeal
TRINEUROSOL HP INJ - Animeal
Rx Required
🚚 FREE delivery on orders above ₹499
10 DaysEasy Returns
100%Authentic
SecurePayments
INJECTABLE

TRINEUROSOL HP INJ

By WOCKHARDT
₹ 59.15
You save ₹ 6.58 (10%)
MRP ₹ 65.73 (Incl. taxes)

Out of Stock

Expires on or after: Jul, 2025
Size
₹ 59.15
MRP ₹ 65.73  10% OFF
1
Check Availability

Trineurosol-HP Injection is a standout product in our VETERINARY VITAMIN INJECTABLE category. Crafted with utmost pharmaceutical precision by Tridoss Laboratories Pvt. Ltd. a trusted Indian pharmaceutical manufacturer this injectable delivers Hydroxocobalamin, the most biologically superior and clinically preferred form of parenteral Vitamin B12, directly into the systemic circulation via intramuscular or subcutaneous injection bypassing the gastrointestinal absorption pathway that is frequently impaired in the very animals that need B12 supplementation most. Unlike Cyanocobalamin the cheaper and more commonly used synthetic B12 form Hydroxocobalamin is the naturally occurring, biologically active cobalamin that binds directly to plasma proteins for superior tissue retention, has a significantly longer plasma half-life that reduces injection frequency requirements, and does not require hepatic conversion before becoming biologically active. For animals with pancreatic exocrine insufficiency, chronic intestinal malabsorption, inflammatory bowel disease, or severe dietary B12 deficiency conditions where oral B12 supplementation is completely ineffective parenteral Hydroxocobalamin injection is the only reliable therapeutic option for achieving and maintaining adequate tissue B12 levels. With Trineurosol-HP, you can trust that you are offering every animal patient the very best in pharmaceutical-grade, biologically superior parenteral B12 repletion.

Composition:

Each 1ml ampoule of Trineurosol-HP Injection contains a precisely formulated, pharmaceutical-grade composition for reliable parenteral delivery:

  • Hydroxocobalamin 1000mcg/ml (Active Ingredient): the naturally occurring, biologically active form of Vitamin B12 distinguished from the synthetic Cyanocobalamin form by its superior pharmacokinetic profile in three clinically important ways. First, Hydroxocobalamin binds avidly to transcobalamin transport proteins in plasma, achieving significantly higher and more sustained tissue B12 concentrations than Cyanocobalamin following injection. Second, its longer plasma half-life means effective therapeutic B12 tissue concentrations are maintained for significantly longer periods between injections reducing treatment frequency requirements and improving practical compliance in clinical practice. Third, unlike Cyanocobalamin which must first be converted to Hydroxocobalamin or Methylcobalamin by hepatic metabolism before becoming biologically active, Hydroxocobalamin enters the active coenzyme pool directly delivering faster, more complete, and more reliable therapeutic action in the two critical B12-dependent enzymatic pathways: the methylcobalamin pathway (methionine synthesis, DNA methylation, and folate metabolism) and the adenosylcobalamin pathway (propionate metabolism and the methylmalonyl-CoA to succinyl-CoA conversion essential for neurological myelin sheath maintenance)
  • Sodium Chloride IP (Isotonic Vehicle): a pharmaceutical-grade isotonic saline base that maintains the osmolality of the injectable solution within the physiological range ensuring minimal tissue irritation, vascular compatibility, and patient comfort upon intramuscular or subcutaneous injection
  • Glacial Acetic Acid / Sodium Acetate (pH Buffer): a pharmaceutical buffer system that maintains the solution pH at the optimal range for Hydroxocobalamin stability and parenteral bioavailability preventing chemical degradation of the active ingredient during storage and ensuring complete solubility and stability at the time of injection
  • Water for Injection IP (Sterile Vehicle): sterile, pyrogen-free water meeting Indian Pharmacopoeia standards for parenteral preparations the aqueous base delivering the active ingredient in a completely clear, injectable solution free from particulate matter and microbial contamination

Definitive Treatment for Vitamin B12 Deficiency Anaemia: the single most important and clinically validated veterinary application of parenteral Hydroxocobalamin providing rapid, complete, and reliable correction of B12 deficiency megaloblastic and macrocytic anaemia in dogs, cats, and large animals where oral B12 supplementation cannot be reliably absorbed. Haematological response including reticulocytosis, rising haemoglobin, and normalisation of red blood cell morphology is typically observed within the first 5 to 10 days of initiating parenteral B12 therapy

Essential Support for Exocrine Pancreatic Insufficiency (EPI): one of the most clinically important veterinary indications for parenteral B12 in dogs EPI causes profound malabsorption of dietary Vitamin B12 through multiple mechanisms including loss of intrinsic factor secretion, bacterial overgrowth consuming dietary B12, and mucosal malabsorption. Virtually all dogs with EPI have significant B12 deficiency that cannot be corrected by oral supplementation alone, making regular parenteral Hydroxocobalamin injection an essential component of comprehensive EPI management alongside enzyme replacement therapy

Chronic Intestinal Malabsorption & Inflammatory Bowel Disease: cats and dogs with chronic enteropathies, protein-losing enteropathy, severe IBD, and intestinal lymphangiectasia frequently develop clinically significant B12 deficiency due to impaired ileal absorption of the B12-intrinsic factor complex parenteral Hydroxocobalamin bypasses this impaired absorptive pathway entirely, delivering therapeutic B12 directly into the systemic circulation regardless of gastrointestinal absorptive status

Neurological Support & Peripheral Neuropathy Management: Vitamin B12 is the essential cofactor for adenosylcobalamin-dependent enzymes responsible for maintaining the structural and functional integrity of the myelin sheath that insulates peripheral nerve axons. B12 deficiency causes progressive demyelination of peripheral nerves resulting in weakness, ataxia, proprioceptive deficits, and sensory neuropathy parenteral Hydroxocobalamin arrests this neurological deterioration and supports myelin repair and remyelination when initiated before irreversible axonal damage occurs

Recovery Support in Debilitated, Post-Surgical & Chronically Ill Animals: the B-complex metabolic roles of Vitamin B12 in energy metabolism, protein synthesis, and DNA replication make it an important supportive supplement for debilitated, post-surgical, anorexic, and chronically ill animals requiring intensive nutritional rehabilitation supporting faster recovery, improved appetite, and restoration of cellular metabolic function

Supports Appetite Stimulation & Weight Gain: clinical experience consistently demonstrates that B12-deficient animals particularly cats with chronic disease and dogs with EPI show significant improvement in appetite, food intake, and body weight following correction of B12 deficiency with parenteral Hydroxocobalamin, as B12 plays a fundamental role in the hypothalamic regulatory pathways that control appetite and satiety

Superior Plasma Retention & Tissue Saturation vs Cyanocobalamin: the significantly superior plasma protein binding and longer half-life of Hydroxocobalamin compared to Cyanocobalamin means that a single therapeutic injection achieves higher peak tissue B12 concentrations that are maintained for longer delivering more complete tissue B12 saturation and a more durable therapeutic response with fewer injections required to maintain adequate B12 status in deficient patients

Cyanide Antidote Action: a unique additional clinical property of Hydroxocobalamin not shared by other B12 forms the cobalt centre of Hydroxocobalamin has an extremely high binding affinity for cyanide ions, forming the stable, non-toxic cyanocobalamin compound that is safely eliminated in urine. This property has been exploited in emergency medicine for cyanide poisoning antidote therapy a use that veterinarians may encounter in cases of smoke inhalation or toxic plant ingestion in companion animals

How to Use:

For intramuscular (IM) or subcutaneous (SC) administration by or under the direct supervision of a licensed veterinarian only. Inspect each ampoule visually before use the solution should be clear, deep red in colour, and free from particulate matter. Do not use if the solution appears cloudy, discoloured, or contains visible particles. Draw the required dose into a sterile syringe using aseptic technique. Administer by deep intramuscular injection into an appropriate injection site or by subcutaneous injection as clinically appropriate. Protect drawn solution from light Hydroxocobalamin is photosensitive and should be administered promptly after drawing into the syringe.

Storage Advice:

Store Trineurosol-HP Injection below 25°C in a cool, dry place. Protect strictly from light Hydroxocobalamin is highly photosensitive and exposure to light causes rapid chemical degradation and loss of potency. Store in the original carton until the point of use. Do not freeze. Keep out of reach of children. Do not use after the expiry date printed on the ampoule label and outer carton. Use immediately after opening do not store opened or partially used ampoules.

About the Brand:

Trineurosol-HP is manufactured by Tridoss Laboratories Pvt. Ltd. a trusted Indian pharmaceutical manufacturer with a strong track record of delivering consistent quality pharmaceutical injectable formulations to healthcare professionals and veterinarians across India. With manufacturing facilities operating under strict GMP quality standards and a commitment to pharmaceutical-grade active ingredient purity and concentration accuracy in every ampoule, Tridoss Laboratories ensures that every dose of Trineurosol-HP delivers the reliable, precisely dosed, biologically superior Hydroxocobalamin that veterinarians and their animal patients depend upon for consistent therapeutic outcomes. Their commitment to accessible, quality-assured pharmaceutical manufacturing aligns perfectly with Animeal's mission to provide registered veterinary professionals across India with reliable procurement access to the full spectrum of veterinary pharmaceutical needs.

Disclaimer:

Trineurosol-HP Injection is a prescription-only injectable medicine that must be prescribed and administered exclusively by or under the direct supervision of a licensed veterinarian. It is not available for self-administration or over-the-counter dispensing. Vitamin B12 deficiency in companion animals is frequently a clinical sign of significant underlying disease including exocrine pancreatic insufficiency, inflammatory bowel disease, intestinal lymphangiectasia, and chronic enteropathy that requires comprehensive veterinary diagnosis and management beyond B12 supplementation alone. Always investigate and address the underlying cause of B12 deficiency in parallel with parenteral B12 repletion therapy. Serum Vitamin B12 measurement before and during therapy is recommended where available to guide therapeutic decision-making and monitor response. Animeal facilitates enquiry and procurement for registered veterinary professionals this product is available for veterinary clinic and hospital procurement only.

Q: Why is Hydroxocobalamin preferred over Cyanocobalamin for veterinary parenteral B12 therapy?
Hydroxocobalamin offers three clinically important pharmacokinetic advantages over the more commonly available and cheaper Cyanocobalamin form. First, it binds avidly to plasma transcobalamin proteins, achieving higher peak tissue B12 concentrations and maintaining them for significantly longer following injection. Second, its longer plasma half-life means effective therapeutic B12 tissue levels are maintained between injections for a more extended period reducing injection frequency requirements and improving practical treatment compliance. Third, unlike Cyanocobalamin which requires hepatic conversion before becoming biologically active, Hydroxocobalamin enters the active coenzyme pool directly delivering faster and more complete therapeutic action in the methylcobalamin and adenosylcobalamin pathways critical for haematological and neurological health respectively.
Q: How quickly will I see clinical improvement after starting parenteral B12 therapy in a B12-deficient dog or cat?
The haematological response to parenteral Hydroxocobalamin therapy in B12-deficient animals is typically rapid and clinically measurable. A reticulocytosis (increase in immature red blood cell precursors in circulation the first sign of haematopoietic recovery) is usually detectable within 5 to 7 days of the first injection. Rising haemoglobin and improving packed cell volume are typically measurable within 2 to 3 weeks. Clinical improvement in appetite, energy level, and body weight in dogs with EPI and cats with chronic disease is often noticed by owners within 2 to 4 weeks of initiating regular parenteral B12 therapy. Neurological improvement in animals with B12 deficiency neuropathy is typically slower requiring 4 to 8 weeks of therapy and is only achievable if treatment is initiated before irreversible axonal damage has occurred.
Q: Why can't B12-deficient animals with EPI or IBD simply take oral B12 supplements instead of injections?
In healthy animals with intact gastrointestinal function, dietary Vitamin B12 absorption occurs through a complex process involving intrinsic factor secretion by the pancreas and stomach, B12-intrinsic factor complex formation, and specific receptor-mediated absorption in the ileum. In dogs with EPI, this process is severely impaired through multiple mechanisms loss of pancreatic intrinsic factor secretion, secondary small intestinal bacterial overgrowth consuming dietary B12 before it can be absorbed, and mucosal malabsorption. In cats and dogs with IBD and chronic enteropathy, ileal mucosal damage impairs receptor-mediated absorption of the B12-intrinsic factor complex. In both conditions, oral B12 supplementation regardless of dose cannot reliably achieve or maintain adequate serum and tissue B12 levels, making parenteral injection the only therapeutically reliable route for B12 repletion in these patients.
Q: Is long-term parenteral B12 supplementation safe for dogs and cats?
Yes Vitamin B12 is a water-soluble vitamin with an extremely wide therapeutic index and no known toxicity at any clinically relevant dose in dogs or cats. Excess Hydroxocobalamin that is not bound to plasma proteins and tissue receptors is safely eliminated in the urine. Long-term monthly or bi-monthly parenteral B12 maintenance therapy is routinely and safely used in dogs with EPI and cats with chronic intestinal disease throughout their entire lives with no adverse effects associated with long-term use. Regular monitoring of serum B12 levels where available helps optimise injection frequency and confirm that maintenance therapy is achieving adequate tissue B12 saturation.
Q: How can veterinary clinics procure Trineurosol-HP Hydroxocobalamin 1000mcg Injection through Animeal?
Registered veterinary practitioners, veterinary clinics, and animal hospitals can enquire about and procure Trineurosol-HP Injection through Animeal's dedicated veterinary pharmaceutical enquiry channel. Please use the Enquire Now button on this product page or contact our veterinary pharma team directly via WhatsApp or phone with your valid veterinary prescription and practice registration details. Our team will respond promptly with product availability, current pricing, pack size options, and delivery arrangements to your registered clinic or hospital address anywhere across India.
TRINEUROSOL HP INJ
₹ 59.15
₹ 65.73  10% OFF

Frequently Asked Questions

Why is Hydroxocobalamin preferred over Cyanocobalamin for veterinary parenteral B12 therapy?

Hydroxocobalamin offers three clinically important pharmacokinetic advantages over the more commonly available and cheaper Cyanocobalamin form. First, it binds avidly to plasma transcobalamin proteins, achieving higher peak tissue B12 concentrations and maintaining them for significantly longer following injection. Second, its longer plasma half-life means effective therapeutic B12 tissue levels are maintained between injections for a more extended period reducing injection frequency requirements and improving practical treatment compliance. Third, unlike Cyanocobalamin which requires hepatic conversion before becoming biologically active, Hydroxocobalamin enters the active coenzyme pool directly delivering faster and more complete therapeutic action in the methylcobalamin and adenosylcobalamin pathways critical for haematological and neurological health respectively.

How quickly will I see clinical improvement after starting parenteral B12 therapy in a B12-deficient dog or cat?

The haematological response to parenteral Hydroxocobalamin therapy in B12-deficient animals is typically rapid and clinically measurable. A reticulocytosis (increase in immature red blood cell precursors in circulation the first sign of haematopoietic recovery) is usually detectable within 5 to 7 days of the first injection. Rising haemoglobin and improving packed cell volume are typically measurable within 2 to 3 weeks. Clinical improvement in appetite, energy level, and body weight in dogs with EPI and cats with chronic disease is often noticed by owners within 2 to 4 weeks of initiating regular parenteral B12 therapy. Neurological improvement in animals with B12 deficiency neuropathy is typically slower requiring 4 to 8 weeks of therapy and is only achievable if treatment is initiated before irreversible axonal damage has occurred.

Why can't B12-deficient animals with EPI or IBD simply take oral B12 supplements instead of injections?

In healthy animals with intact gastrointestinal function, dietary Vitamin B12 absorption occurs through a complex process involving intrinsic factor secretion by the pancreas and stomach, B12-intrinsic factor complex formation, and specific receptor-mediated absorption in the ileum. In dogs with EPI, this process is severely impaired through multiple mechanisms loss of pancreatic intrinsic factor secretion, secondary small intestinal bacterial overgrowth consuming dietary B12 before it can be absorbed, and mucosal malabsorption. In cats and dogs with IBD and chronic enteropathy, ileal mucosal damage impairs receptor-mediated absorption of the B12-intrinsic factor complex. In both conditions, oral B12 supplementation regardless of dose cannot reliably achieve or maintain adequate serum and tissue B12 levels, making parenteral injection the only therapeutically reliable route for B12 repletion in these patients.

Is long-term parenteral B12 supplementation safe for dogs and cats?

Yes Vitamin B12 is a water-soluble vitamin with an extremely wide therapeutic index and no known toxicity at any clinically relevant dose in dogs or cats. Excess Hydroxocobalamin that is not bound to plasma proteins and tissue receptors is safely eliminated in the urine. Long-term monthly or bi-monthly parenteral B12 maintenance therapy is routinely and safely used in dogs with EPI and cats with chronic intestinal disease throughout their entire lives with no adverse effects associated with long-term use. Regular monitoring of serum B12 levels where available helps optimise injection frequency and confirm that maintenance therapy is achieving adequate tissue B12 saturation.

How can veterinary clinics procure Trineurosol-HP Hydroxocobalamin 1000mcg Injection through Animeal?

Registered veterinary practitioners, veterinary clinics, and animal hospitals can enquire about and procure Trineurosol-HP Injection through Animeal's dedicated veterinary pharmaceutical enquiry channel. Please use the Enquire Now button on this product page or contact our veterinary pharma team directly via WhatsApp or phone with your valid veterinary prescription and practice registration details. Our team will respond promptly with product availability, current pricing, pack size options, and delivery arrangements to your registered clinic or hospital address anywhere across India.
View All Questions